Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Operating Leases came in at $14.1 million in Q1 2026, down 21.22% YoY from $17.9 million in Q1 2025, and down 6.5% on a QoQ basis from $15.1 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 7 years of Operating Leases data on file, last reported at $14.1 million in Q1 2026.
- Quarterly Operating Leases fell 21.22% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (down 21.22% YoY) and the FY2025 annual result came in at $15.1 million, down 19.77% from the prior year.
- Operating Leases fell to $14.1 million in Q1 2026, from $15.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $28.8 million in Q2 2022 to a low of $14.1 million in Q1 2026.
- A 5-year average of $21.8 million and a median of $23.0 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 115.65% — and 2025, when it plunged 30.28%.
- Tracing BDTX's Operating Leases over 5 years: stood at $25.3 million in 2022, then dropped by 12.31% to $22.2 million in 2023, then decreased by 15.34% to $18.8 million in 2024, then declined by 19.77% to $15.1 million in 2025, then declined by 6.5% to $14.1 million in 2026.
- The last three Operating Leases figures came in at $14.1 million (Q1 2026), $15.1 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.10 Mn |
| Mar 31, 2026 | 14.09 Mn |
| Dec 31, 2025 | 15.07 Mn |
| Sep 30, 2025 | 16.04 Mn |
| Jun 30, 2025 | 16.97 Mn |
| Mar 31, 2025 | 17.88 Mn |
| Dec 31, 2024 | 18.78 Mn |
| Sep 30, 2024 | 23.00 Mn |
| Jun 30, 2024 | 23.78 Mn |
| Mar 31, 2024 | 21.36 Mn |
| Dec 31, 2023 | 22.19 Mn |
| Sep 30, 2023 | 23.00 Mn |
| Jun 30, 2023 | 23.78 Mn |
| Mar 31, 2023 | 27.45 Mn |
| Dec 31, 2022 | 25.30 Mn |
| Sep 30, 2022 | 26.04 Mn |
| Jun 30, 2022 | 28.85 Mn |
| Mar 31, 2022 | 27.45 Mn |
| Dec 31, 2021 | 28.14 Mn |
| Sep 30, 2021 | 29.68 Mn |